First Results From a Randomized Phase 2 Study of Cabazitaxel vs an Androgen Receptor-Targeted Agent in Patients With Poor-Prognosis Castration-Resistant Prostate Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [31] Use of zoledronic acid therapy-associated severe hypophosphatemia to identify poor-prognosis patients with metastatic castration-resistant prostate cancer
    Warr, Julia
    Yam, David
    Goodall, Shannon
    VanDraanen, Leah
    Giotis, Angie
    Pasetka, Mark
    De Angelis, Carlo
    Emmenegger, Urban
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [32] Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
    Oudard, Stephane
    Fizazi, Karim
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjorn
    Hjalm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel
    Mainwaring, Paul N.
    Bernard, John
    Shen, Liji
    Chadjaa, Mustapha
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3189 - +
  • [33] Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
    Hussain, Maha
    Daignault-Newton, Stephanie
    Twardowski, Przemyslaw W.
    Albany, Costantine
    Stein, Mark N.
    Kunju, Lakshmi P.
    Siddiqui, Javed
    Wu, Yi-Mi
    Robinson, Dan
    Lonigro, Robert J.
    Cao, Xuhong
    Tomlins, Scott A.
    Mehra, Rohit
    Cooney, Kathleen A.
    Montgomery, Bruce
    Antonarakis, Emmanuel S.
    Shevrin, Daniel H.
    Corn, Paul G.
    Whang, Young E.
    Smith, David C.
    Caram, Megan V.
    Knudsen, Karen E.
    Stadler, Walter M.
    Feng, Felix Y.
    Chinnaiyan, Arul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (10) : 991 - +
  • [34] Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer
    Scher, Howard I.
    Beer, Thomasz
    Higano, Celestia S.
    Danila, Daniel C.
    Shelkey, Julia
    Hirmand, Mohammed
    Hung, David
    Morris, Michael J.
    Larson, Steve M.
    Sawyers, Charles L.
    CANCER RESEARCH, 2008, 68 (09)
  • [35] Androgen Receptor (AR) anomalies and efficacy of apalutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study
    Mainwaring, Paul N.
    Smith, Matthew R.
    Thomas, Shibu
    Chowdhury, Simon
    Olmos, David
    Li, Jinhui
    Oudard, Siephane
    Feng, Felix Y.
    Gormley, Michael
    Ricci, Deborah S.
    Rooney, Brendan
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Small, Eric J.
    BJU INTERNATIONAL, 2018, 122 : 6 - 7
  • [36] Efficacy of docetaxel and androgen receptor axis-targeted agents in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
    Yamamoto, Akiyuki
    Kato, Masashi
    Tsuzuki, Toyonori
    Gotoh, Momokazu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
    Annala, M.
    Fu, S.
    Bacon, J. V. W.
    Sipola, J.
    Iqbal, N.
    Ferrario, C.
    Ong, M.
    Wadhwa, D.
    Hotte, S. J.
    Lo, G.
    Tran, B.
    Wood, L. A.
    Gingerich, J. R.
    North, S. A.
    Pezaro, C. J.
    Ruether, J. D.
    Sridhar, S. S.
    Kallio, H. M. L.
    Khalaf, D. J.
    Wong, A.
    Beja, K.
    Schonlau, E.
    Taavitsainen, S.
    Nykter, M.
    Vandekerkhove, G.
    Azad, A. A.
    Wyatt, A. W.
    Chi, K. N.
    ANNALS OF ONCOLOGY, 2021, 32 (07) : 896 - 905
  • [38] Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer
    Laber, Damian A.
    Chen, Min-Bin
    Jaglal, Michael
    Patel, Ankita
    Visweshwar, Nathan
    CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : 473 - 481
  • [39] YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients
    Afonso, Ana
    Silva, Jani
    Lopes, Ana Rita
    Coelho, Sara
    Patrao, Ana Sofia
    Rosinha, Alina
    Carneiro, Filipa
    Pinto, Ana Rita
    Mauricio, Maria Joaquina
    Medeiros, Rui
    PHARMACOGENOMICS, 2020, 21 (13) : 919 - 928
  • [40] Influence of the sequence of cabazitaxel therapy on the outcome of patients with metastatic castration-resistant prostate cancer - First interim results of the non-interventional SCOPE study
    Bokemeyer, C.
    Lange, C.
    Gschwend, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 76 - 77
12345